Positive Results From Study Administering Cord Blood To Children With Hearing Loss.
SOUTH SAN FRANCISCO, Calif., September. 18, 2018- CBR (Cord Blood Registry) announced publication of the results of a clinical trial evaluating the use of autologous umbilical cord blood in children with acquired sensorineural hearing loss (SNHL).
The researchers reported that cord blood infusions were safe, feasible, and well tolerated.
In addition, 45 percent of participants showed improvements on Auditory Brainstem Response (ABR) after their infusion.
SNHL is defined as hearing loss due to damage or dysfunction of the inner ear (as opposed to other structures of the ear). This can be a result of premature birth, infections, or exposure to noise or ototoxic drugs, resulting in irreversible damage to the fragile hair cells (cilia) in the inner ear.
The study, published in August 2018, was funded by CBR, California Cryobank company.
The Phase 1 pilot study assessed the safety and preliminary efficacy of infusions of autologous umbilical cord blood in 11 children with acquired SNHL.
"We found a statistically significant improvement in a measure of hearing based on one of the tests we performed," said James Baumgartner. "This may be an indication that newborn stem cells help the ear repair itself in some children with hearing loss."
The study provides the first clinical evidence in humans to support this hypothesis, according to Baumgartner.
"Although the exact mechanism of action is unknown, unique properties of the cord blood cellular components are believed to spur regeneration of the cilia (hair) and support cells within the cochlea."
Although hearing aids or cochlear implants help to improve the ability to hear in individuals who have SNHL, these current interventions don't address the underlying cause. Currently, there is no cure for SNHL.
"A child's hearing ability affects the development of language skills and future academic and social development," said Linda Baumgartner.
Approximately 15 percent of children have some form of low or high frequency hearing loss, and 40 percent of young adults with hearing loss experience a limit in daily functioning.
"These preliminary findings build on results from previous animal model studies that demonstrated human umbilical cord blood helps restore hearing function," said Jaime Shamonki, chief medical officer of CBR and California Cryobank Life Sciences. "Given the pilot nature of this study, participants were not paired with matched controls. However, given that SNHL does not improve with age or other therapies, ABR thresholds would not be expected to improve spontaneously in these children, regardless of concurrent use of hearing aids or speech therapy. We have good reason to believe that cord blood stem cells played a role in improving ABR in these children."
Citation: Linda S. Baumgartner et al., Safety of Autologous Umbilical Cord Blood Therapy for Acquired Sensorineural Hearing Loss in Children. Journal of Audiology and Otology, 2018;22(4):209-222, published online: August 22, 2018, DOI: 10.7874/jao.2018.00115
Contact: James E. Baumgartner, email@example.com
|Printer friendly Cite/link Email Feedback|
|Publication:||Stem Cell Research News|
|Date:||Oct 8, 2018|
|Previous Article:||Strong Survival Outcomes At Six Months In Phase 3 Trial For Acute GvHD.|
|Next Article:||Improved Approach To Bone Marrow Transplant.|